DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Albert David Limited (ALBERTDAVD) share price today?

Albert David Limited (ALBERTDAVD) is trading at ₹828.05 on the NSE, up 4.72% on the day. Source: DocStoX.

What is the PE ratio of Albert David Limited?

Albert David Limited has a price-to-earnings (PE) ratio of 21.6 in the Healthcare sector.

What is the market capitalisation of Albert David Limited?

Albert David Limited has a market capitalisation of approximately ₹474 crore.

Is Albert David Limited a profitable company?

Albert David Limited generates a return on equity of -0.4% with a net profit margin of -0.4%. That is a modest return on shareholder capital.

What is the 52-week high and low of ALBERTDAVD?

Albert David Limited (ALBERTDAVD) has traded between ₹579.9 and ₹931.85 over the past 52 weeks, against a current price of ₹828.05.

Does Albert David Limited pay a dividend?

Yes. Albert David Limited currently offers a dividend yield of 0.59%. Dividend payments depend on the board's declaration each year.

Albert David Limited

₹828.05▲ +37.35 (+4.72%)

ALBERTDAVD·NSE·Healthcare

Market Cap

474.27 Cr

PE Ratio

21.60

Volume

3,281

Day High - Low

836.95 - 787.00

52W High-Low

931.85 - 579.90

₹828.05▲ +37.35 (+4.72%)

Market Cap474.27 Cr

PE Ratio21.60

Volume3,281

Day High - Low836.95 - 787.00

52W High-Low931.85 - 579.90

Albert David Limited (ALBERTDAVD): company summary

The company's annual revenue fell 3.3% year-over-year, but the latest quarter saw revenue rise 42.7% compared to the same quarter a year earlier.

Albert David Limited (ALBERTDAVD) is a micro-cap Healthcare company valued at ₹474 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Albert David Limited last traded at ₹828.05, up 4.72% on the day.
Recent developments: On 2026-07-30, the company announced a dividend of ₹5.00 per share, ex-date. The latest financial year ended on 2026-03-31, reporting a net loss of ₹1 crore. The latest quarter ended on 2026-06-30, showing a significant improvement in net profit compared to the same quarter a year earlier.
Financial performance: The company's annual revenue fell 3.3% year-over-year, but the latest quarter saw revenue rise 42.7% compared to the same quarter a year earlier. Net profit swung from a profit of ₹17 crore to a loss of ₹1 crore annually, while the latest quarter recorded a net profit of ₹32 crore, up 300.0% from ₹8 crore a year ago. Margins have deteriorated sharply, with the net profit margin at -0.4% compared to 4.9% the prior year.
Valuation multiples: The stock trades at 21.6 times earnings, a discount to the Healthcare median of 32.0, 1.25 times book value. It yields 0.6%.
Things to watch: The company reported a net loss of ₹1 crore in its latest financial year, marking a sharp decline from a net profit of ₹17 crore the prior year. The net profit margin has fallen to -0.4%, down 5.4 percentage points from 4.9%. The stock is 8.1% below its 52-week high, and the latest quarter's net profit growth of 300.0% contrasts with an annual net profit loss.
Where it stands: The company's latest quarter showed a strong rebound in net profit, rising 300.0% compared to the same quarter a year earlier, but annual results remain weak with a net loss of ₹1 crore. The stock is 8.1% below its 52-week high, and the net profit margin has deteriorated to -0.4%. The most significant movement is the sharp rise in net profit in the latest quarter.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

4.3/10

Weak

Fair Value

ROE

-0.38%

Weak

P/E

21.60x

Fair

Debt / Equity

0.07

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

Day₹787.00

₹836.95

52W₹579.90

₹931.85

DocStoX take

Supported by momentum (7.5) and risk (6.4), but held back by quality (1.4). Momentum looks strong at 7.5, but that is offset by quality at 1.4 and growth at 2.9. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

4.3

/10

Weak

Quality

Weak

ROE -0.4%

Valuation

Fair

P/E 21.6×

Growth

Flat

Revenue +6.3% 5Y CAGR

Risk

Moderate

D/E 0.07

Momentum

Strong

71% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹828

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹474 Cr

52W High / Low

₹932 / ₹580

Dividend Yield

0.59%

Promoter Holding

62.24%

EPS (TTM)

₹38.34

Book Value

₹686.04

Key highlights

Low leverage — D/E 0.07
Quality is weak (1.4/10)
Small ₹474 cr company — thinner liquidity

1 Positive2 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore ALBERT DAVID LIMITED’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

ALBERT DAVID LIMITED peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD LAURUS LABS LIMITED CIPLA LTD DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD MANKIND PHARMA LIMITED LUPIN LIMITED MANIPAL HEALTH ENTERPRI L

Compare ALBERT DAVID LIMITED with peers

ALBERT DAVID LIMITED vs SUN PHARMACEUTICAL IND L ALBERT DAVID LIMITED vs DIVI S LABORATORIES LTD ALBERT DAVID LIMITED vs TORRENT PHARMACEUTICALS L ALBERT DAVID LIMITED vs APOLLO HOSPITALS ENTER. L ALBERT DAVID LIMITED vs ZYDUS LIFESCIENCES LTD ALBERT DAVID LIMITED vs LAURUS LABS LIMITED

Related tools & concepts

Value ALBERT DAVID LIMITED with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

ALBERTDAVD newsLatest coverage & filings Open screenerFilter the whole market